Panvel Farmácias (Dimed S.A.) stock surges on Q4 2025 earnings beat with 17% annual sales growth and record EBITDA

Dimed S.A., operator of Panvel Farmácias, reported robust Q4 2025 results including 17% full-year sales growth and a record BRL105 million EBITDA, driving investor interest amid GLP-1 supply challenges. ISIN: BRPNVLACNOR5. US investors eye Brazil's pharmacy retail expansion and digital sales boom at 54% Q4 share.

Dimed S.A., the company behind Panvel Farmácias, released Q4 2025 earnings on March 20, 2026, showcasing 17% full-year sales growth in a tough Brazilian market. The Panvel Farmácias (Dimed S.A.) stock reacted positively on the B3 exchange in BRL, reflecting market approval of record Q4 EBITDA near BRL105 million, up 28% quarter-over-quarter. For US investors, this highlights resilient pharmacy retail growth in South America, with digital channels now at 54% of Q4 sales and own-brand products powering 20% of hygiene and beauty revenue.

As of: 25.03.2026

By Elena Vargas, Senior Latin America Retail Analyst: Dimed's pivot to digital and private-label strength positions Panvel Farmácias as a standout in Brazil's competitive pharmacy sector amid rising GLP-1 drug demand.

Q4 2025 Earnings Deliver Record Results Amid Market Headwinds

Dimed S.A. posted impressive Q4 2025 figures, with EBITDA hitting a record nearly BRL105 million, a 28% increase from the prior quarter. Full-year sales grew 17%, defying Brazil's challenging economic environment marked by inflation pressures and supply chain issues. Panvel Farmácias maintained a strong 14% market share in southern Brazil, consolidating its regional dominance through targeted expansion and customer loyalty programs.

Digital sales emerged as a standout, comprising 54% of Q4 revenue and contributing to a 28.5% overall sales share from online channels. This shift underscores Dimed's successful adaptation to e-commerce trends, accelerated by post-pandemic consumer habits. Own Panvel products drove nearly 20% of hygiene and beauty sales, boosting margins via higher-value private labels less vulnerable to generic competition.

The results stem from operational efficiencies and strategic focus on high-growth categories. Management highlighted balanced portfolio growth, avoiding over-reliance on any single product line. This performance sets a strong foundation for 2026, with analysts noting Dimed's ability to navigate retail pharmacy dynamics effectively.

GLP-1 Supply Constraints and Margin Pressures in Focus

GLP-1 drugs like Mounjaro represent 11% of Dimed's sales, with supply restrictions persisting but stabilizing as Brazil gains priority from suppliers like Lilly. CFO Antonio Carlos Tocchetto Napp noted generics entering around June 2026 could expand the market threefold, countering the informal sector's dominance. Dimed mitigated margin erosion through generics growth and Panvel brands, preserving comfortable gross margins.

Competitive pressures from GLP-1 expansion challenge profitability, as these high-demand weight-loss drugs carry lower margins. The counterfeit GLP-1 market, three times larger than formal channels, poses additional risks to authentic sales. Management emphasized a diversified mix, with GLP-1 not positioned as the sole growth engine.

Working capital outlook remains steady, with inventory cycles stabilizing at 90 days and collection periods at 30 days. Supplier terms are improving, supporting cash flow amid category shifts. These dynamics illustrate Dimed's proactive risk management in a high-stakes pharma retail landscape.

Long-Term Ambitions: Doubling Revenue by 2030

CEO Julio Ricardo Mottin Neto outlined a bold vision to double revenue to BRL12 billion by 2030, expanding to 1,000 stores while lifting EBITDA margins to 7%. Digital growth, customer loyalty, and Panvel brand extension form the core strategy. This trajectory positions Dimed for sustained compounding in Brazil's fragmented pharmacy market.

Regional consolidation in the South, at 14% share, provides a launchpad for national scaling. Investments in store formats and omnichannel integration aim to capture shifting consumer preferences. Management's focus on execution risks underscores disciplined capital allocation.

Pilot programs like a five-day workweek have boosted employee satisfaction, potentially aiding retention amid Brazil's proposed labor reforms. Productivity concerns from reduced hours are monitored closely, with changes expected to unfold gradually. These initiatives support operational resilience.

Transition from Wholesale to Retail Pure-Play

Dimed's shift from wholesale to retail focus presents both opportunities and execution hurdles. Wholesale legacy provides supply chain expertise, now leveraged for retail efficiency. This evolution enhances direct customer access, improving data-driven inventory and pricing.

Challenges include maintaining growth momentum post-transition, with retail demanding higher fixed costs for stores and marketing. Success hinges on same-store sales growth and new unit economics. Panvel's brand equity mitigates these risks, fostering loyalty in competitive urban markets.

South Brazil's affluent demographics favor premium pharmacy services, aligning with Dimed's upscale positioning. Expansion into adjacent states tests scalability, with real estate and regulatory approvals as key variables. Management's track record instills confidence in navigating this pivot.

Why US Investors Should Watch Panvel Farmácias Closely

Brazil's pharmacy sector offers diversification for US portfolios seeking emerging market retail exposure. Dimed's 17% growth outpaces many US peers amid economic volatility, driven by demographics and healthcare access expansion. Digital penetration at 54% mirrors US trends, providing familiar growth levers.

GLP-1 category parallels US obesity drug booms, with Brazil's informal market signaling untapped potential. As generics arrive, Dimed's scale positions it to capture formalization gains. Currency hedges and ETF access ease entry for US investors via B3 ADRs or funds.

Valuation discipline, with EBITDA margin expansion targets, appeals to value-oriented strategies. South American retail scarcity enhances appeal versus saturated US markets. Monitoring macroeconomic ties like Brazil-US trade supports informed allocation.

Risks and Open Questions Ahead

Supply volatility for GLP-1s remains a wildcard, potentially capping short-term sales if restrictions linger. Margin pressures from competition and counterfeits demand vigilant mix management. Labor reforms pose productivity risks, though pilots show promise.

Execution on 2030 goals faces real estate inflation and regulatory hurdles in expansion. Macro factors like Brazilian interest rates impact consumer spending. Transition risks could pressure near-term cash flows if retail ramp lags.

Overall, Dimed's strengths mitigate these, but diversified exposure remains prudent. Investors should track Q1 2026 updates for GLP-1 progress and digital metrics.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.